Showing results (401-410 of 409) with videos related to
Sort By:
Pageof 41
You have reached the last page of results.This site can display upto 409 results.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 10, 2017
Complement Alternative Pathway Deficiency in Recipients Protects Kidney Allograft From Ischemia/Reperfusion Injury and Alloreactive T Cell ResponseF Casiraghi, N Azzollini, M Todeschini, et al.American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|April 16, 2014
An unanticipated role for survivin in organ transplant damageP Cassis, S Solini, N Azzollini, et al.Kidney International|September 5, 2001
Proteinuria as a modifiable risk factor for the progression of non-diabetic renal diseaseT H Jafar, P C Stark, C H Schmid, et al.The British Journal of Dermatology|March 30, 2010
PTCH1 gene haplotype association with basal cell carcinoma after transplantationA Begnini, G Tessari, A Turco, et al.American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|November 2, 2007
Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor HH Jalanko, S Peltonen, A Koskinen, et al.Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|March 24, 2005
[Renal transplantation in the North Italy Transplant program (NITp): Organ allocation and results]M Cardillo, F Barraco, N De Fazio, et al.Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|April 23, 2002
The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)B M Brenner, M E Cooper, D de Zeeuw, et al.Annals of Internal Medicine|July 17, 2001
Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level dataT H Jafar, C H Schmid, M Landa, et al.The New England Journal of Medicine|June 7, 2013
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndromeC M Legendre, C Licht, P Muus, et al.Pageof 41